All treatments
Treatment
Lenvatinib, Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants with First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (nccRCC) (KEYNOTE-B61)
This study is looking at a new combination of two medicines, Lenvatinib and KEYTRUDA, for adults with a type of kidney cancer called non-clear cell renal cell carcinoma (nccRCC). It’s in an early stage of testing to see how well patients respond to the treatment.
For: Non-clear Cell Renal Cell CarcinomaItaly · Spain · Hungary - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II single-arm study of pembrolizumab plus lenvatinib in previously treated classic Kaposi sarcoma (CKS)
This study is looking at a new combination treatment for a type of cancer called Kaposi sarcoma that has come back or not responded to previous treatments. It uses two drugs, pembrolizumab and lenvatinib, to see how well they work together.
For: Advanced unresectable classic Kaposi sarcoma relapsed and/or refractory to previous standard treatments.Italy